


Please amend page 29 line 1 as follows:

Claims What is claimed is:

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Original) A compound of formula (I):



wherein

R^2 is




wherein b is an integer of from 0 to 10;

R^3 is a C_{1-4} alkylene or C_{2-4} alkenylene bridge;

W_1 is absent or represents a spacer moiety which is a C_{1-30} hydrocarbyl group optionally including 1 to 10 heteroatoms selected from oxygen, nitrogen, and sulphur, and is


preferentially derived from glutaric and/or succinic acid and/or a polyethyleneglycol based unit and/or a unit of Formula :



Z_1 is an antineoplastic agent, a chelating agent or a reporter moiety.


2. (Original) A compound of formula (I) according to claim 1, wherein Z_1 is a reporter moiety comprising a radionuclide.

3. (Original) A compound of formula (Ia):




wherein

R^1 is either a bond or is



wherein a is an integer of from 1 to 30;

R² is



wherein b is an integer of from 0 to 10;

R³ is a C₁₋₄ alkylene or C₂₋₄ alkenylene bridge;

the Linker is a C₁₋₃₀ hydrocarbyl group optionally including 1 to 10 heteroatoms.

4. (Original) A compound of formula (Ia) according to claim 3 in which:

R³ is C₁₋₄ alkylene;

a is an integer of from 1 to 10; and



b is 1.

5. (Currently amended) A compound of formula (Ia) according to claim 3 ~~or 4~~ in which:

R³ is -CH₂-; and

a is 5.

6. (Currently amended) A compound of formula (Ia) according to ~~any of claims 3 to 5~~ claim 3 in which the Linker is selected from (II), (III) and (IV) :




wherein:

n is an integer of 1 to 20;

m is an integer of 1 to 10;
 p is an integer of 1 to 20;
 q is an integer of 0 to 4;
 r is an integer of 1 to 10.

7. (Currently amended) A compound of formula (Ia) according to ~~any of claims 3 to 6~~ claim 3 which is:




8. (Currently amended) A compound of formula (I) ~~or (Ia)~~ according to ~~any of claims 1 to 7~~ claim 1 for use in medicine, particularly in the *in vivo* diagnosis or imaging, for example by PET, of a disease or condition associated with angiogenesis.


9. (Currently amended) A method for *in vivo* diagnosis or imaging of a disease or condition associated with angiogenesis which comprises the step of administering a compound of formula (I) ~~or (Ia)~~ according to ~~any of claims 1 to 7~~ claim 1 to a human or animal body, followed by generation of an image, suitably a PET image, of part or all of said body

10. (Currently amended) A radiopharmaceutical formulation comprising a compound of formula (I) ~~or (Ia)~~ according to ~~any of claims 1 to 7~~ claim 1 and one or more pharmaceutically acceptable excipients.

11. (Currently amended) A method of preparing a compound of formula (Ia) as defined in ~~any of claims 3 to 7~~ claim 3 which comprises reaction of the corresponding compound of formula (V):



wherein R^1 , R^2 , and R^3 are as defined for the compound of formula (Ia) and X is a leaving group selected from chloro, bromo, and iodo, and is preferably chloro;
by reaction with the appropriate compound of formula (VI):



wherein the Linker is as defined for the compound of formula (Ia).

12. (Original) A compound of formula (V) as defined in claim 11.

13. (Currently amended) A kit for the preparation of a radiofluorinated peptide of formula (Ia) according to ~~any of claims 3 to 7~~ claim 3 comprising:

(i) a compound of formula (VIa)




wherein L is a leaving group such as p-toluenesulphonate, trifluoromethanesulphonate, or methanesulphonate,

the Linker is a C_{1-30} hydrocarbyl group optionally including 1 to 10 heteroatoms;

R is hydrogen or a thiol protecting group;




and

(ii) an activated peptide of formula (V) ~~as defined in claim 11~~



14. (Currently amended) A kit according to claim 13, comprising:

(i) a compound of formula (VIb), (VIc), or (VIId):



n is an integer of 1 to 20;

m is an integer of 1 to 10;

p is an integer of 1 to 20;

q is an integer of 0 to 4;

r is an integer of 1 to 10;

L is a leaving group such as p-toluenesulphonate, trifluoromethanesulphonate, or methanesulphonate;

L' is a leaving group such as iodo, p-toluenesulphonate, trifluoromethanesulphonate, or methanesulphonate and when q is 0, L' can be nitro or an iodonium or ammonium salt,

R is hydrogen or a thiol protecting group; and

(ii) an activated peptide of formula (V) ~~as defined in claim 11~~

